Floatz logo

DACLIZUMAB

Chemotherapy

Abramson Cancer Center at Penn Medicinemonoclonal_antibodyEarly Phase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

8 Active assets in the Chemotherapy cohort.

Asset / SponsorPhaseRating
D-thioctic acid
Ain Shams University
Phase 4BB
DL-6,8-THIOCTIC ACID
Ain Shams University
Phase 4BB
TAMOXIFEN
Merck Sharp & Dohme LLC
Phase 2/3B
Hdepa
Sun Yat-sen University
Phase 3B
Ldepa
Sun Yat-sen University
Phase 3B

View all 17 →

Same molecule, other indications

DACLIZUMAB is also rated in:

relapsing-remitting multiple sclerosisDormant
BB
Indicative ·
68 / 100
View asset →
HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL)Dormant
BB
Indicative ·
68 / 100
View asset →
relapsing-remitting multiple sclerosisDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →